麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

丹麥Santaris Pharma
Santaris Pharma是一家丹麥的臨床階段的生物制藥公司。公司成立于2003年，有著LNA技術的專利權LNA技術是第三代的反義核酸化學技術，用于開發新品種的RNA藥物，也稱RNA拮抗劑。Santaris Pharma已經開發了mRNA拮抗劑和microRNA拮抗劑，用于沉默與各種疾病如癌癥、代謝紊亂、病毒感染相關的mRNA和microRNA。Santaris Pharma在2006年5月完成了第二階段四千萬歐元的融資，并在2007年12月第三階段融資兩千萬歐元。Santaris Pharma與新澤西的Enzon制藥公司有著全球合作，來開發和商業化一系列Santaris Pharma RNA拮抗劑，并與GlaxoSmithKline結成戰略同盟，開探索、開發和商業化針對病毒疾病的新型藥物。

Santaris Pharma is dedicated to the exciting new field of RNA-therapeutics, and is ready to deliver on the promise of the technology today. Our proprietary Locked Nucleic Acid Drug Platform and state-of-the-art Drug Discovery Engine are transforming the field of RNA-based medicines, making safe and effective modulation of disease-related RNAs an achievable goal.

The Company's drug development pipeline is focused on improving the treatment and outcome of patients with metabolic disorders and infectious diseases. In collaboration with our strategic partners, we are engaged in a broad array of additional therapeutic areas such as cancer, inflammatory diseases and rare genetic disorders.